10-Q/A: Grace Therapeutics Corrects Share Count in Amended Quarterly Report
10-Q/A Amendment
Grace Therapeutics files an amendment to its Form 10-Q to correct the number of outstanding shares of common stock as of December 31, 2024.
Summary
- Grace Therapeutics has filed an amendment (Form 10-Q/A) to its original Form 10-Q for the quarter ended December 31, 2024.
- The sole purpose of the amendment is to correct the number of outstanding shares of common stock reported on the cover page of the original filing.
- The correct number of outstanding shares as of February 12, 2025, is 13,416,735.
- No other changes were made to the original filing, and the amendment includes new certifications from the CEO and Principal Financial Officer.
Sentiment
Score: 7
Explanation: The document is a routine correction, so the sentiment is neutral. The correction of an error is a positive sign of diligence.
Future Outlook
There is no future outlook provided in this document, as it is solely focused on correcting a previously reported number.
Industry Context
This announcement is a routine correction to a previously filed financial report. It does not indicate any broader industry trends or competitive dynamics.
Stakeholder Impact
- The correction of the share count ensures accurate information for shareholders.
Key Dates
| Date | Description |
|---|---|
| June 27, 2024 | Filing date of Acasti Pharma Inc.'s Registration Statement on Form S-4 (referenced for Indemnification Agreement). |
| October 7, 2024 | Filing date of Current Report on Form 8-K (referenced for Certificate of Incorporation). |
| October 28, 2024 | Filing date of Current Report on Form 8-K (referenced for Certificate of Amendment to the Certificate of Incorporation and Bylaws). |
| December 31, 2024 | End of the quarterly period for the original Form 10-Q. |
| February 12, 2025 | Date for the corrected number of outstanding shares: 13,416,735. |
| February 13, 2025 | Filing date of the original Form 10-Q. |
| February 18, 2025 | Date of the amended filing (Form 10-Q/A). |
| March 31, 2025 | Q3 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.